US EditionAMA panel calls for transparency, federal oversight to address rapid AI expansion
- The American Medical Association panel met in 2025 to discuss the rapid expansion of AI in healthcare and its regulatory challenges in the US.
- This panel convened because AI adoption has outpaced regulation, raising concerns about liability, transparency, and patient privacy risks.
- Panelists highlighted AI's use in prior authorization processes, noting mixed impacts such as expedited approvals versus increased denial rates.
- They cited data showing 61% of physicians worry AI will increase denials, while 82% say prior authorization delays can cause patients to abandon treatment.
- The panel urged federal and state transparency and oversight to ensure safe AI deployment, stressing that physicians remain responsible for patient outcomes.
11 Articles
11 Articles
AMA panel calls for transparency, federal oversight to address rapid AI expansion
As use of artificial intelligence grows rapidly in health care, the American Medical Association brought together an expert panel to highlight policy changes, transparency concerns and implications for physician practices.
Inside the FDA's plans to embrace AI agencywide
OpenAI has been connecting with various companies in an effort to incorporate its generative artificial intelligence technology, and federal agencies are rumored to be part of that effort. While a contract with Open AI has yet to be confirmed, the Food and Drug Administration is suggesting that AI will be a part of its operations sooner rather than later. FDA seeking 'aggressive' adoption of AI The FDA announced an "aggressive timeline" to deplo…
FDA Deploying AI to Accelerate Drug Approvals
In a sweeping internal reform, the U.S. Food and Drug Administration (FDA) has launched its first agency-wide deployment of artificial intelligence for drug review. Last Friday, Commissioner Dr. Martin Makary announced that all FDA centers must “aggressively” and “immediately” integrate generative AI by June 30, following the agency’s first pilot review using the technology. “I ... The post FDA Deploying AI to Accelerate Drug Approvals appeared …
FDA AI deployment: Innovation vs oversight in drug regulation
The US Food and Drugs Administration (FDA) has stated that it wants to accelerate the deployment of AI across its centres. FDA Commissioner Martin A. Makary has announced an aggressive timeline to scale use of AI by 30 June 2025 and is betting big on the technology to change drug approval processes for the US. But the rapid AI deployment at the FDA raises important questions about whether… Source
FMG Leading Highlights Human-Centered Strategies for Healthcare Tech Adoption
PHILADELPHIA, PA — FMG Leading has released its Spring 2025 Healthcare Insights Report, emphasizing the need for healthcare organizations to align human capital strategies with their technology investments. Titled “Leading Healthcare in the AI Era: People Strategies to Ensure Tech Investments Deliver,” the report provides actionable recommendations for bridging people and technology to enhance clinical, operational, and financial outcomes. The r…
Coverage Details
Bias Distribution
- 33% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
